INTRODUCTION
============

Sarcopenia increases the risk of not only diverse metabolic diseases including diabetes mellitus (DM)[@b1-jomes-28-046],[@b2-jomes-28-046] but also cardiovascular diseases[@b3-jomes-28-046] and long-term mortality.[@b4-jomes-28-046] In the last decade, it has been reported that muscle quality as well as muscle mass is important in metabolic health[@b5-jomes-28-046]--[@b7-jomes-28-046], and the measurement of muscle strength is one easy way to evaluate muscle quality.[@b8-jomes-28-046],[@b9-jomes-28-046] Muscle strength is significantly associated with metabolic health[@b6-jomes-28-046],[@b7-jomes-28-046], low cardiovascular events[@b10-jomes-28-046],[@b11-jomes-28-046], and low all-cause mortality.[@b5-jomes-28-046],[@b10-jomes-28-046] Furthermore, the Health, Aging and Body Composition study, which was designed to determine the role of body composition changes in the risk of poor health outcomes, showed that muscle strength is more important than muscle mass for predicting mortality.[@b5-jomes-28-046]

Body mass index (BMI) has been reported to be associated with muscle strength in diverse populations: absolute strength is higher in obese versus nonobese individuals[@b12-jomes-28-046]--[@b15-jomes-28-046], which implicates that the presence of obesity should be considered in the analysis of the association between muscle strength and metabolic disease. We investigated the relationship between muscle strength and the prevalence of DM according to obesity status among participants in the Korea National Health and Nutrition Examination Survey (KNH-ANES) from 2014 to 2016. As aging is one of the most important determining factors for both of muscle strength and diabetes, we used age-specific cutoff values for the definition of low muscle strength (LMS).

METHODS
=======

Subjects
--------

The KNHANES is conducted on noninstitutionalized Korean civilians using a stratified multistage probability-based sampling design.[@b16-jomes-28-046] To ensure the results best represent the entire Korean population, weights are assigned to each respondent.[@b17-jomes-28-046] For this study, we selected the KNHANES 2014 to 2016 data which provide the handgrip strength of participants. Based on the numbers of participants in the 2014, 2015, and 2016 KNHANESs (n= 7,550, 8,150, and 8,127, respectively), weights for the combined dataset were recalculated. Subjects aged 30 to 79 years were selected and, after excluding subjects whose handgrip strength was unavailable, 13,149 participants were finally included in our study. The KNHANES 2014 was approved by the Institutional Review Board (IRB) of the Korean Centers for Disease Control (IRB No. 2013-12EXP-03-5C). Separately, for the 2015 and 2016 KNHANESs, IRB approval was not required under the Bioethics Act.

Metabolic parameter measurement
-------------------------------

The precise methods for the measurement of clinical parameters were reported previously.[@b18-jomes-28-046] Briefly, cases of DM were defined as subjects who were using antidiabetic medications including insulin at the time of the survey, had hemoglobin A1c values of 48 mmol/mol (6.5%) or more, or had 8-hour fasting plasma glucose levels of 7.0 mmol/L or more. Hypertriglyceridemia was defined as a fasting triglyceride level of 150 mg/dL or more, while low high-density lipoprotein (HDL) cholesterol was defined as that less than 40 mg/dL and less than 50 mg/dL in male and female, respectively, according to the National Cholesterol Education Program criteria.[@b19-jomes-28-046] Additionally, abdominal obesity was defined as a waist circumference of 90 cm or more and 85 cm or more in male and female, respectively[@b20-jomes-28-046], and metabolic syndrome was defined based on the revised National Cholesterol Education Program Adult Treatment Panel III criteria.[@b19-jomes-28-046] Hypertension was defined as a blood pressure of 140/90 mmHg or more or the use of antihypertensive medication. BMI was classified based on the World Health Organization's Asia-Pacific criteria, with that of 25 kg/m^2^ or greater indicating obesity.[@b21-jomes-28-046]

Measurement of handgrip strength
--------------------------------

Handgrip strength was measured three times in each individual both in the dominant and nondominant arms using a digital grip strength dynamometer (TKK 5401; Takei, Tokyo, Japan) which can measure force between 5.0 and 100.0 kg. During the assessment, participants were instructed to stand upright with their feet placed hip-width apart, to look forward with the elbow fully extended, and to squeeze the grip continuously with full force for at least 3 seconds. The resting time between each measurement was at least 60 seconds. Muscle strength in each individual was defined as the average of handgrip strength of dominant hand (kg) from three trials, and its quartiles (Qs) were calculated in each sex at every 10 years of age (i.e., 30--39, 40--49, 50--59, 60--69, and 70--79 years). Q1 and Q4 were the lowest and highest Qs of handgrip strength, respectively; Q1 was specifically defined as the subjects with LMS.

Statistical analyses
--------------------

All data were analyzed using the SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). The results are presented in the format of mean (standard error \[SE\]) or prevalence (% and SE). Sampling weights were used to account for complex sampling and applied to all regression analyses. Logistic regression analysis adjusted for age, obesity, and other risk factors was used to identify differences in the prevalence of diabetes with respect to muscle strength Q. Linear regression analysis was used to analyze the associations between continuous variables and muscle strength Q. The level of significance was set at *P*\<0.05.

RESULTS
=======

Clinical characteristics according to muscle strength
-----------------------------------------------------

The mean age of the study population aged 30 to 79 years of the 2014 to 2016 KNHANESs, was 50.7 years (SE, 0.2 years), and 49.4% (SE, 0.4%) were male. The prevalences of DM and obesity were 13.5% (SE, 0.4%) and 36.0% (SE, 0.5%), respectively. Mean handgrip strength of the dominant arm was 43.6 kg (SE, 0.3 kg) and 25.4 kg (SE, 0.1 kg) in male and female aged 30 to 39 years ([Table 1](#t1-jomes-28-046){ref-type="table"}); by contrast, that of male and female aged 70 to 79 years was 30.9 kg (SE, 0.3 kg) and 18.7 kg (SE, 0.2 kg), respectively. Overall, as age increased, the mean handgrip strength decreased significantly irrespectively of sex or dominant/nondominant arm (all *P*\<0.001) ([Table 1](#t1-jomes-28-046){ref-type="table"}). Considering the age-dependency of muscle strength, an age-adjusted handgrip strength parameter was thought appropriate for use in the further analyses. For that, Qs of handgrip strength were calculated for each sex encompassing ranges of 10 years of age (i.e., 30--39, 40--49, 50--59, 60--69, and 70--79 years) ([Supplementary Table 1](#s1-jomes-28-046){ref-type="supplementary-material"} and [Fig. 1](#f1-jomes-28-046){ref-type="fig"}). LMS was defined as the lowest Q (Q1) of the dominant arm.

There was no difference in age among individuals in the various handgrip strength Qs (*P*=0.101 and *P*=0.167 in male and female, respectively) ([Table 2](#t2-jomes-28-046){ref-type="table"}). As muscle strength increased, BMI and the prevalence of obesity, hypertriglyceridemia, and metabolic syndrome increased significantly according to crude analysis (*P*\< 0.01) ([Table 2](#t2-jomes-28-046){ref-type="table"}). By contrast, the prevalence of DM decreased in both sexes (*P*= 0.039 and *P*=0.019 in male and female, respectively) ([Table 2](#t2-jomes-28-046){ref-type="table"}).

The prevalence of obesity increased by 30% in male (odds ratio \[OR\], 1.300; 95% confidence interval \[CI\], 1.231--1.373; *P*\<0.001) and 12% in female (OR, 1.122; 95% CI, 1.062--1.185; *P*\<0.001) per one Q of muscle strength ([Supplementary Table 2](#s1-jomes-28-046){ref-type="supplementary-material"}). By contrast, the prevalence of DM decreased as muscle strength increased (OR per one Q, 0.926; 95% CI, 0.862--0.996; *P*=0.039 in male and OR per one Q, 0.917; 95% CI, 0.854--0.986; *P*=0.019 in female).

The prevalence of diabetes according to LMS and obesity
-------------------------------------------------------

LMS was significantly associated with DM in crude analysis (OR, 1.248; 95% CI, 1.094--1.423; *P*=0.001), which remained statistically significant even after adjustment for age, sex, family history of DM, abdominal obesity, dyslipidemia, and hypertension (OR, 1.328; 95% CI, 1.133--1.558). An independent association between LMS and diabetes was found, irrespective of age ([Supplementary Table 3](#s1-jomes-28-046){ref-type="supplementary-material"}).

As obesity was positively associated with muscle strength in both sexes ([Supplementary Table 2](#s1-jomes-28-046){ref-type="supplementary-material"}), we subsequently analyzed the association between LMS and DM according to the presence or absence of obesity. Stratified analysis according to obesity status showed that LMS was significantly associated with diabetes in nonobese individuals (OR, 1.444; 95% CI, 1.205--1.731; *P*\< 0.001) but not in those with obesity (OR, 1.200; 95% CI, 0.982--1.468; *P*=0.075) ([Table 3](#t3-jomes-28-046){ref-type="table"}). Adjustment for age, sex, family history of DM, abdominal obesity, dyslipidemia, and hypertension also confirmed a significant association between diabetes and LMS only in those without obesity (OR, 1.513; 95% CI, 1.224--1.870; *P*\<0.001 and OR, 1.124; 95% CI, 0.879--1.437; *P*=0.351 in nonobese and obese participants, respectively) ([Table 3](#t3-jomes-28-046){ref-type="table"}). Further BMI-stratified analyses in nonobese individuals confirmed that an independent association between LMS and diabetes was only found in those with a BMI of less than 23 kg/m^2^ ([Supplementary Table 4](#s1-jomes-28-046){ref-type="supplementary-material"}).

In the obese population, age (*P*\<0.001), male sex (*P*=0.024), family history of diabetes (OR, 2.653; 95% CI, 2.142--3.287), abdominal obesity (OR, 1.751; 95% CI, 1.371--2.236), hypertriglyceridemia (OR, 1.547; 95% CI, 1.244--1.922), low HDL cholesterolemia (OR, 1.476; 95% CI, 1.176--1.854), and hypertension (OR, 1.621; 95% CI, 1.315--1.999) were significantly associated with the presence of diabetes in multivariable analysis ([Table 3](#t3-jomes-28-046){ref-type="table"}).

DISCUSSION
==========

In the current study, muscle strength was significantly associated with BMI irrespective of sex. Although high muscle strength positively correlated with the prevalence of obesity, it was significantly associated with a low risk of DM even after making adjustments for risk factors. Obesity-stratified analysis revealed that the protective effect of muscle strength for DM was found only in those without obesity. There was no significant association between muscle strength and DM in the obese population.

Currently, muscle strength for the definition of sarcopenia is based on the absolute muscle strength: the suggested cutoffs for handgrip strength are less than 26 kg for males, and less than 16 kg for females per the Foundation for the National Institutes of Health Biomarkers Consortium Sarcopenia Project[@b9-jomes-28-046], or less than 27 kg for males and less than 16 kg for females per the European Working Group on Sarcopenia in Older People[@b8-jomes-28-046], respectively. However, there may exist ethnic differences in the reference ranges for muscle strength.[@b22-jomes-28-046] In addition, in the case of middle-aged individuals, muscle strength can affect metabolic health and mortality even if above the range indicating sarcopenia[@b23-jomes-28-046]; therefore, age-specific definitions of LMS should be considered for the prediction of health outcomes among age-matched populations. We defined age-specific LMS using a nationwide database representative of the Korean population, and found that it had an independent association with DM in the nonobese group.

A previous study using KNHANES data applied a unifying definition of LMS considering the entire population irrespective of age and also found a significant association between LMS and diabetes.[@b7-jomes-28-046] The authors[@b7-jomes-28-046] used weight-normalized muscle strength; however, the relationship between body mass and muscle strength might be different between obese and nonobese individuals.[@b15-jomes-28-046] Furthermore, one's handgrip ability is relatively independent of weight-bearing movement, and no difference of absolute handgrip power between obese and nonobese subjects was reported.[@b15-jomes-28-046]

Interestingly, in the current study, the association between muscle strength and diabetes was significant only in the nonobese population. Obesity is a well-known and strong risk factor for developing diabetes[@b24-jomes-28-046], and it was positively correlated with muscle strength in the current study, which might attenuate the effect of muscle strength on diabetes. Obesity was defined according to BMI in the current study, and BMI is based on body weight. As BMI cannot differentiate between individuals with large muscle mass or large fat mass[@b25-jomes-28-046], some number of those individuals with obesity may in fact have large muscle mass, which attenuates the effect of muscle strength on diabetes in those with obesity in the current study. However, further stratified analysis according to BMI in those without obesity confirmed that an independent association between LMS and diabetes was only found in those with a BMI of less than 23 kg/m^2^, which also suggests LMS might be more important in those with low BMI.

The current study has several limitations. The first one is its cross- sectional nature. We could not determine the causality in the association between LMS and the risk of diabetes because of the combined cross-sectional study design. As skeletal muscle is the primary tissue responsible for insulin-mediated glucose disposal, low skeletal muscle mass reduces insulin-mediated glucose disposal, independent of obesity. The independent association between skeletal muscle and insulin resistance has been confirmed by previous epidemiological[@b26-jomes-28-046],[@b27-jomes-28-046] and experimental[@b28-jomes-28-046] studies. The second limitation is that we had no data on muscle mass. There were no data available on body composition from the 2014 to 2016 KNHANESs. Muscle mass is another important determinant of sarcopenia and has been reported to increase the risk of Dm^2^, cardiovascular diseases[@b3-jomes-28-046], and long-term mortality.[@b4-jomes-28-046] However, a previous study confirmed that muscle strength is more important than muscle mass for future clinical outcomes[@b5-jomes-28-046], and we successfully showed that an independent association exists between diabetes and LMS in a nonobese population.

In conclusion, LMS was independently associated with DM in a Korean population aged between 30 and 79 years old. Obesity-stratified analysis revealed that it was significant only in the nonobese population, which suggests that, even in the nonobese population, LMS might be a risk factor for developing diabetes. Resistance training can be an efficient tool for the prevention of diabetes in the population with normal body weight.
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![Handgrip strength according to age in subjects 30 to 79 years old in the 2014 to 2016 Korea National Health and Nutrition Examination Surveys. Median strength (kg) with interquartile range in each age group is represented.](jomes-28-046f1){#f1-jomes-28-046}

###### 

Handgrip strength (kg) in each age group

  Age (yr)                                                    Male       Female                                     
  ----------------------------------------------------------- ---------- ---------- --------- ---------- ---------- ---------
  30--39                                                      43.6±0.3   41.6±0.2   \<0.001   25.4±0.1   24.1±0.1   \<0.001
                                                                                                                    
  40--49                                                      42.5±0.2   40.8±0.2   \<0.001   25.1±0.1   23.8±0.1   \<0.001
                                                                                                                    
  50--59                                                      39.6±0.2   38.2±0.2   \<0.001   24.0±0.1   22.7±0.1   \<0.001
                                                                                                                    
  60--69                                                      36.4±0.2   35.1±0.2   \<0.001   22.1±0.1   20.8±0.1   \<0.001
                                                                                                                    
  70--79                                                      30.9±0.3   30.1±0.2   \<0.001   18.7±0.2   17.8±0.2   \<0.001
                                                                                                                    
  *P* for trend[†](#tfn3-jomes-28-046){ref-type="table-fn"}   \<0.001    \<0.001              \<0.001    \<0.001    

Values are presented as mean±standard error.

Wilcoxon signed-rank test to compare handgrip strength between dominant arm and nondominant arm;

From logistic regression for complex sample.

###### 

Clinical characteristics according to the Qs of handgrip strength

  Variable                       1Q         2Q         3Q         4Q         *P*[\*](#tfn5-jomes-28-046){ref-type="table-fn"}
  ------------------------------ ---------- ---------- ---------- ---------- --------------------------------------------------
  Male                                                                       
   Unweighted N                  1,479      1,459      1,466      1,456      
   Handgrip strength, D (kg)     31.4±0.2   38.2±0.1   42.3±0.1   48.5±0.2   \<0.001
   Handgrip strength, ND (kg)    31.7±0.2   37.0±0.1   40.3±0.1   45.5±0.2   \<0.001
   Age (yr)                      50.4±0.4   49.9±0.4   49.8±0.4   49.5±0.4   0.101
   BMI (kg/m^2^)                 23.8±0.1   24.4±0.1   24.7±0.1   25.4±0.1   \<0.001
   Obesity (%)                   32.2±1.5   38.5±1.5   42.3±1.6   51.9±1.4   \<0.001
   Diabetes mellitus (%)         17.6±1.1   14.1±1.1   14.6±1.0   14.1±1.0   0.039
   Hypertension (%)              30.2±1.4   34.6±1.4   32.7±1.5   34.9±1.5   0.064
   Hypertriglyceridemia (%)      42.2±1.5   43.6±1.6   44.5±1.5   46.8±1.5   0.029
   Low HDL cholesterolemia (%)   26.2±1.4   24.4±1.4   24.1±1.3   24.4±1.4   0.368
   Metabolic syndrome (%)        35.8±1.5   37.0±1.5   39.5±1.5   42.9±1.5   \<0.001
                                                                             
  Female                                                                     
   Unweighted N                  1,835      1,842      1,785      1,827      
   Handgrip strength, D (kg)     17.8±0.1   22.4±0.1   25.3±0.1   29.5±0.1   \<0.001
   Handgrip strength, ND (kg)    17.7±0.1   21.4±0.1   23.7±0.1   27.3±0.1   \<0.001
   Age (yr)                      51.2±0.4   50.9±0.4   50.9±0.4   50.5±0.4   0.167
   BMI (kg/m^2^)                 23.3±0.1   23.2±0.1   23.6±0.1   24.2±0.1   \<0.001
   Obesity (%)                   29.1±1.3   26.5±1.1   29.8±1.3   36.1±1.4   \<0.001
   Diabetes mellitus (%)         12.7±0.9   11.8±0.8   9.9±0.8    10.5±0.8   0.019
   Hypertension (%)              23.8±1.2   23.7±1.1   25.8±1.2   25.5±1.1   0.155
   Hypertriglyceridemia (%)      21.7±1.3   22.2±1.1   22.2±1.2   23.4±1.2   \<0.001
   Low HDL cholesterolemia (%)   40.8±1.4   38.6±1.4   36.1±1.2   43.4±1.3   0.326
   Metabolic syndrome (%)        27.3±1.3   27.3±1.2   26.7±1.2   32.5±1.3   0.007

Values are presented as mean or prevalence±standard error.

Logistic and linear regression analysis without any adjustment.

Q, quartile; D, dominant arm; ND, nondominant arm; BMI, body mass index; HDL, high-density lipoprotein.

###### 

OR for diabetes mellitus in the stratified analysis according to the presence or absence of obesity

  Variable                      Unadjusted             Multivariable regression analysis[\*](#tfn7-jomes-28-046){ref-type="table-fn"}                          
  ----------------------------- ---------------------- -------------------------------------------------------------------------------- ---------------------- ---------
  Nonobese                                                                                                                                                     
   Low muscle strength          1.444 (1.205--1.731)   \<0.001                                                                          1.513 (1.224--1.870)   \<0.001
   Family history of diabetes   2.355 (1.993--2.783)   \<0.001                                                                          3.532 (2.838--4.394)   \<0.001
   Abdominal obesity            3.046 (2.491--3.724)   \<0.001                                                                          1.386 (1.039--1.849)   0.027
   Hypertriglyceridemia         2.852 (2.443--3.329)   \<0.001                                                                          2.088 (1.683--2.591)   \<0.001
   Low HDL cholesterolemia      2.175 (1.863--2.539)   \<0.001                                                                          1.565 (1.261--1.943)   \<0.001
   Hypertension                 3.919 (3.378--4.546)   \<0.001                                                                          1.610 (1.318--1.967)   \<0.001
   Age                          1.078 (1.072--1.085)   \<0.001                                                                          1.079 (1.070--1.089)   \<0.001
   Sex (female)                 0.578 (0.500--0.669)   \<0.001                                                                          0.556 (0.454--0.681)   \<0.001
                                                                                                                                                               
  Obese                                                                                                                                                        
   Low muscle strength          1.200 (0.982--1.468)   0.075                                                                            1.124 (0.879--1.437)   0.351
   Family history of diabetes   2.180 (1.812--2.622)   \<0.001                                                                          2.653 (2.142--3.287)   \<0.001
   Abdominal obesity            2.165 (1.770--2.649)   \<0.001                                                                          1.751 (1.371--2.236)   \<0.001
   Hypertriglyceridemia         1.453 (1.240--1.701)   \<0.001                                                                          1.547 (1.244--1.922)   \<0.001
   Low HDL cholesterolemia      1.657 (1.387--1.979)   \<0.001                                                                          1.476 (1.176--1.854)   0.001
   Hypertension                 2.369 (2.006--2.798)   \<0.001                                                                          1.621 (1.315--1.999)   \<0.001
   Age                          1.048 (1.042--1.055)   \<0.001                                                                          1.051 (1.042--1.059)   \<0.001
   Sex (female)                 0.930 (0.793--1.090)   0.370                                                                            0.795 (0.651--0.970)   0.024

Age, sex, muscle strength, family history of diabetes, abdominal obesity, hypertriglyceridemia, low HDL cholesterolemia, and hypertension were included in the multivariable regression analysis.

OR, odds ratio; CI, confidence interval; HDL, high-density lipoprotein.
